Rhode Island Chronicle

Uterine Leiomyosarcoma Pipeline | Companies – Novartis, PharmMar, and Others

 Breaking News
  • No posts were found

Uterine Leiomyosarcoma Pipeline | Companies – Novartis, PharmMar, and Others

June 01
08:10 2023
Uterine Leiomyosarcoma Pipeline | Companies - Novartis, PharmMar, and Others

DelveInsight’s, “Uterine Leiomyosarcoma Pipeline Insight 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Uterine Leiomyosarcoma pipeline landscape. It covers the Uterine Leiomyosarcoma pipeline drug profiles, including Uterine Leiomyosarcoma clinical trials and nonclinical stage products. It also covers the Uterine Leiomyosarcoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.


To explore more information on the latest breakthroughs in the Uterine Leiomyosarcoma Pipeline treatment landscape of the report, click here @ Uterine Leiomyosarcoma Pipeline Outlook


Key Takeaways from the Uterine Leiomyosarcoma Pipeline Report

  • DelveInsight’s Uterine Leiomyosarcoma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Uterine Leiomyosarcoma.
  • The leading Uterine Leiomyosarcoma Companies include Novartis, PharmMar, and Others
  • Promising Uterine Leiomyosarcoma Pipeline Therapies include Trabectedin, Letrozole, and others.
  • The primary form of treatment for a Uterine Leiomyosarcoma is surgical removal of the entire tumor and any affected tissue. Total surgical removal of the uterus (hysterectomy) is usually performed. Anti-cancer drugs used alone or combination (chemotherapy) and radiation therapy have been used to treat individuals with leiomyosarcoma following surgery (adjuvant therapy) with limited benefit. Leiomyosarcomas have a high risk of recurrence, individuals should be examined routinely after surgery.
  • The Uterine Leiomyosarcoma companies and academics are working to assess challenges and seek opportunities that could influence Uterine Leiomyosarcoma R&D. The Uterine Leiomyosarcoma therapies under development are focused on novel approaches to treat/improve Uterine Leiomyosarcoma.


For further information, refer to the detailed Uterine Leiomyosarcoma Unmet Needs, Uterine Leiomyosarcoma Market Drivers, and Uterine Leiomyosarcoma Market Barriers, click here for Uterine Leiomyosarcoma Ongoing Clinical Trial Analysis


Uterine Leiomyosarcoma Overview

A Uterine Leiomyosarcoma (ULMS) is a rare malignant (cancerous) tumor that arises from the smooth muscle lining the walls of the uterus (myometrium). Leiomyosarcoma is classified as a soft tissue sarcoma. Sarcomas are malignant tumors that arise from the connective tissue, which connects, supports and surrounds various structures and organs in the body. Soft tissue includes fat, muscle, never, tendons, tissue surrounding the joints (synovial tissue), and blood and lymph vessels. The exact cause of leiomyosarcoma, including Uterine Leiomyosarcoma, is unknown.


Uterine Leiomyosarcoma Emerging Drugs Profile


  • Trabectedin: PharmMar

Yondelis® (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, a type of sea squirt. Yondelis® exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.


  • Letrozole: Novartis

Letrozole is a non-steroidal type II aromatase inhibitor. It blocks the active site, and therefore the electron transfer chain of CYP19A1. This competitive inhibition prevents the conversion of androgens to estrogen. This action leads to a reduction in uterine weight and elevated leuteinizing hormone.8 In postmenopausal women, the action of aromatase is responsible for the majority of estrogen production. With reduced availability of estrogen, estrogen-dependant tumors regress. Third generation aromatase inhibitors do not significantly affect cortisol, aldosterone, and thyroxine levels. Currently, in phase II of clinical trials.


Request a sample and discover the recent advances in Uterine Leiomyosarcoma Ongoing Clinical Trial Analysis and Medications, click here @ Uterine Leiomyosarcoma Treatment Landscape 


Uterine Leiomyosarcoma Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies for Uterine Leiomyosarcoma. The companies which have their Uterine Leiomyosarcoma drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Novartis and others.


Dive deep into rich insights for drugs for Uterine Leiomyosarcoma Market Drivers and Uterine Leiomyosarcoma Market Barriers, click here @ Uterine Leiomyosarcoma Unmet Needs and Analyst Views


Scope of the Uterine Leiomyosarcoma Pipeline Report

  • Coverage- Global
  • Uterine Leiomyosarcoma Companies- Novartis, PharmMar, and Others
  • Uterine Leiomyosarcoma Pipeline Therapies- Trabectedin, Letrozole, and others
  • Uterine Leiomyosarcoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration


Got Queries? Find out the related information on Uterine Leiomyosarcoma Mergers and acquisitions, Uterine Leiomyosarcoma Licensing Activities @ Uterine Leiomyosarcoma Emerging Drugs, and Recent Trends


Table of Content

  1. Introduction
  2. Executive Summary
  3. Uterine Leiomyosarcoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Uterine Leiomyosarcoma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Uterine Leiomyosarcoma Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Drug profiles in the detailed report…..
  11. Mid Stage Products (Phase II)
  12. Letrozole: Novartis
  13. Drug profiles in the detailed report…..
  14. Pre-clinical and Discovery Stage Products
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Uterine Leiomyosarcoma Key Companies
  18. Uterine Leiomyosarcoma Key Products
  19. Uterine Leiomyosarcoma- Unmet Needs
  20. Uterine Leiomyosarcoma- Market Drivers and Barriers
  21. Uterine Leiomyosarcoma- Future Perspectives and Conclusion
  22. Uterine Leiomyosarcoma Analyst Views
  23. Uterine Leiomyosarcoma Key Companies
  24. Appendix


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services